enGene (ENGN) Competitors $4.75 +0.09 (+1.93%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$4.80 +0.04 (+0.95%) As of 03/27/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ENGN vs. ELVN, NTLA, BGM, RCUS, VIR, RCKT, COLL, XNCR, REPL, and PAHCShould you be buying enGene stock or one of its competitors? The main competitors of enGene include Enliven Therapeutics (ELVN), Intellia Therapeutics (NTLA), Qilian International Holding Group (BGM), Arcus Biosciences (RCUS), Vir Biotechnology (VIR), Rocket Pharmaceuticals (RCKT), Collegium Pharmaceutical (COLL), Xencor (XNCR), Replimune Group (REPL), and Phibro Animal Health (PAHC). These companies are all part of the "pharmaceutical products" industry. enGene vs. Enliven Therapeutics Intellia Therapeutics Qilian International Holding Group Arcus Biosciences Vir Biotechnology Rocket Pharmaceuticals Collegium Pharmaceutical Xencor Replimune Group Phibro Animal Health Enliven Therapeutics (NASDAQ:ELVN) and enGene (NASDAQ:ENGN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, community ranking, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends. Do analysts prefer ELVN or ENGN? Enliven Therapeutics presently has a consensus target price of $38.75, suggesting a potential upside of 80.15%. enGene has a consensus target price of $25.22, suggesting a potential upside of 430.99%. Given enGene's higher possible upside, analysts clearly believe enGene is more favorable than Enliven Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enliven Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20enGene 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in ELVN or ENGN? enGene received 8 more outperform votes than Enliven Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Enliven Therapeutics an outperform vote while only 95.00% of users gave enGene an outperform vote. CompanyUnderperformOutperformEnliven TherapeuticsOutperform Votes11100.00% Underperform VotesNo VotesenGeneOutperform Votes1995.00% Underperform Votes15.00% Does the media refer more to ELVN or ENGN? In the previous week, Enliven Therapeutics had 8 more articles in the media than enGene. MarketBeat recorded 13 mentions for Enliven Therapeutics and 5 mentions for enGene. Enliven Therapeutics' average media sentiment score of 0.97 beat enGene's score of 0.50 indicating that Enliven Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive enGene 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, ELVN or ENGN? Enliven Therapeutics has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500. Comparatively, enGene has a beta of -0.61, suggesting that its stock price is 161% less volatile than the S&P 500. Is ELVN or ENGN more profitable? enGene's return on equity of -16.69% beat Enliven Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Enliven TherapeuticsN/A -29.46% -27.33% enGene N/A -16.69%-14.27% Do insiders and institutionals hold more shares of ELVN or ENGN? 95.1% of Enliven Therapeutics shares are owned by institutional investors. Comparatively, 64.2% of enGene shares are owned by institutional investors. 29.2% of Enliven Therapeutics shares are owned by company insiders. Comparatively, 13.7% of enGene shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has better valuation & earnings, ELVN or ENGN? Enliven Therapeutics is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnliven TherapeuticsN/AN/A-$71.58M-$1.89-11.38enGeneN/AN/A-$55.14M-$1.52-3.13 SummaryenGene beats Enliven Therapeutics on 8 of the 15 factors compared between the two stocks. Remove Ads Get enGene News Delivered to You Automatically Sign up to receive the latest news and ratings for ENGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENGN vs. The Competition Export to ExcelMetricenGeneBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$242.14M$3.04B$5.64B$8.06BDividend YieldN/A1.54%4.57%4.01%P/E Ratio-8.1929.2923.1419.03Price / SalesN/A436.17384.1193.17Price / CashN/A168.6838.1634.64Price / Book0.773.956.954.33Net Income-$55.14M-$71.95M$3.20B$247.06M7 Day Performance-4.23%-3.76%-2.28%-0.37%1 Month Performance-20.97%-10.33%2.88%-3.85%1 Year Performance-71.98%-27.15%10.87%1.27% enGene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENGNenGene3.1056 of 5 stars$4.75+1.9%$25.22+431.0%-72.4%$242.14MN/A-8.1931ELVNEnliven Therapeutics2.8728 of 5 stars$21.04+1.4%$38.25+81.8%+15.5%$1.03BN/A-11.0750News CoverageNTLAIntellia Therapeutics4.4793 of 5 stars$9.58+4.8%$37.56+292.0%-68.9%$991.69M$57.88M-1.76600Analyst RevisionBGMQilian International Holding GroupN/A$10.03+4.5%N/AN/A$975.14M$25.10M0.00298Positive NewsGap UpRCUSArcus Biosciences2.507 of 5 stars$9.15-2.0%$30.25+230.5%-53.5%$962.43M$258M-2.91500VIRVir Biotechnology3.6051 of 5 stars$7.01-2.0%$35.67+408.8%-34.0%$961.37M$63.71M-1.79580RCKTRocket Pharmaceuticals4.6678 of 5 stars$8.83+0.8%$43.00+387.0%-71.1%$941.54MN/A-3.21240Positive NewsCOLLCollegium Pharmaceutical4.0759 of 5 stars$29.67+0.7%$43.60+46.9%-27.7%$934.19M$631.45M12.79210Analyst RevisionXNCRXencor3.4825 of 5 stars$12.98+1.7%$34.38+164.8%-48.7%$914.60M$110.49M-4.06280REPLReplimune Group3.8551 of 5 stars$11.78+1.1%$19.43+64.9%+26.7%$907.24MN/A-3.84210Positive NewsPAHCPhibro Animal Health3.9549 of 5 stars$21.85+2.8%$21.00-3.9%+66.0%$884.99M$1.11B45.521,860Analyst DowngradeShort Interest ↓Positive News Remove Ads Related Companies and Tools Related Companies ELVN Competitors NTLA Competitors BGM Competitors RCUS Competitors VIR Competitors RCKT Competitors COLL Competitors XNCR Competitors REPL Competitors PAHC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENGN) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredAI Boom Takes a Shocking Turn…A potentially historic moment for retirement Let's make the most of this market together. Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding enGene Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share enGene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ENGN Stock Free ENGN Stock Alerts